1[1]Li AC, Brown KK, Silvestre MJ, et al. Peroxisome proliferator-activated receptor γ-ligands inhibit development of atherosclerosis in LDL receptor-dificient mice. J Clin Invest,2000,106:523-531.
2[2]Minamikava J, Tanaka S, Yamauchi M, et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab,1998,83:1818-1820.
3[3]Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care,2001,24:683-689.
4[4]Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type Ⅱdiabetes. Diabetes,1996,45:1661-1669.
5[5]Yang C, Chang TJ, Chang JC, et al. Rosiglitazone(BRL 49653) enhances insulin secretory response via phosphatidylinositol 3-kinase pathway. Diabetes,2001,50:2598-2602.
6[6]Oakes ND, Thalén PG, Jacinto SM, et al. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes,2001,50:1158-1165.
7[7]Murakami K, Tobe K, Ide T, et al. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma:effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats . Diabetes,1998,47:1841-1847.
8[8]Combs TP, Wagner JA, Berger J, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: A potential mechanism of insulin sensitization. Endocrinology,2002,143:998-1007.
9[9]Walker AB, Chattington PD, Buckingham RE, et al. The thiazolidinedione rosiglitazone(BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes,1999,48:1448-1453.
10[10]Nordt TK, Peter K, Bode C, et al. Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells. J Clin Endocrinol Metab,2000,85:1563-1568.
